NACFC 2021

For children with cystic fibrosis (CF), newborn screening is associated with markedly improved real-world outcomes, including earlier diagnosis, greater weight and height gains, and fewer bacterial infections, new research demonstrates. In fact, infants are now…

People with cystic fibrosis (CF) who start on the triple therapy Trikafta may be at greater risk of problems associated with excessive weight or obesity, such as metabolic syndrome — a group of disorders known to raise…

Treatment with Orkambi (lumacaftor/ivacaftor) and/or Symdeko (tezacaftor/ivacaftor) may lessen liver damage in children and adolescents with cystic fibrosis (CF) who have liver involvement, new data indicate. “We detected improvements in validated noninvasive biomarkers of liver fibrosis [scarring]…

Treatment with Trikafta can help people with cystic fibrosis (CF) to put on weight, according to new data from a small clinical trial. These findings…

Treatment with SP-101, an investigational gene therapy that Spirovant Sciences is developing for people with cystic fibrosis (CF) who are unable to benefit from current treatments, effectively increased CFTR gene activity in a ferret model of the…

Since the approval of Trikafta in the U.S., Nationwide Children’s Hospital in Ohio has seen a steep increase in the number of women with cystic fibrosis (CF)…